Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer

Purpose: CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). Recently, the Italian Medicines A...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Matteo Lambertini, Massimo Di Maio, Giuseppe Curigliano, Carmen Criscitiello, Saverio Cinieri
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Breast
Subjects:	Breast cancer CDK4-6i Metastatic treatment and endocrine-based therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977625000049
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01)

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
by: Ram Patel, et al.
Published: (2025-01-01)

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors
by: Neha Pathak, et al.
Published: (2025-01-01)

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
by: A. DeMichele, et al.
Published: (2025-01-01)

Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature
by: Jan Fischer, et al.
Published: (2025-01-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study
by: Dinesh Chandra Doval, et al.

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
by: Brenno Pastò, et al.
Published: (2025-02-01)

Diagnostic potential of CDK1 and STAT1 in acute kidney injury associated with gastrointestinal cancers: a bioinformatics-based study
by: Qiuwan Wei, et al.
Published: (2025-01-01)

Thiazolo-pyridopyrimidines: An in silico evaluation as a lead for CDK4/6 inhibition, synthesis and cytotoxicity screening against breast cancer cell lines
by: Chaithra R Shetty, et al.
Published: (2024-07-01)

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01)

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
by: Charlotte K. Kindt, et al.
Published: (2025-01-01)

Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
by: Baković Matea, et al.
Published: (2023-12-01)

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study
by: Akif Doğan, et al.
Published: (2025-01-01)

Multitarget CDK inhibitors roscovitine and UCN‑01 induce apoptosis in colorectal cancer cells by inhibiting cell cycle progression and transcription
by: Sonal Mohan Manohar, et al.
Published: (2025-01-01)

Biosynthesis inhibition of miR-142-5p in a N 6-methyladenosine-dependent manner induces neuropathic pain through CDK5/TRPV1 signaling
by: Jinshi Li, et al.
Published: (2025-01-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

Induction of cell cycle arrest via the p21, p27–cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol
by: Huang Zhiwei, et al.
Published: (2015-12-01)

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context
by: Niels A.D. Guchelaar, et al.
Published: (2025-02-01)

Editorial: New insights into the relationship between endocrine disorders and dental diseases
by: Chaofan Zhang, et al.
Published: (2025-02-01)

Chemicals That Disrupt the Endocrine System and Their Effects on Behavior
by: Yousaf Khan1, Abdul Sattar1, Syed Amin Ullah1, Zia-Ur-Rehman2, Hakimullah3, Madeeha Bibi4, Hina Sarfraz1, Anila Mukhtiar1
Published: (2024-10-01)

Williams Text Book of Endocrinology /
Published: (2016)

Editorial: Cyclic nucleotide phosphodiesterases (PDEs) signaling in the endocrine system
by: Federica Campolo, et al.
Published: (2025-01-01)

The Role Of Time Delays, Slow Processes And Chaos In Modulating The Cell-Cycle Clock
by: E.V. Presnov, et al.
Published: (2005-07-01)

A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
by: Danilo Giffoni de Mello Morais Mata, et al.
Published: (2024-12-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Endocrine disruptors and cancers. [Perturbateurs endocriniens et cancers]
by: Souhila AOUICHAT BOUGUERRA, et al.
Published: (2024-12-01)

Pyriproxyfen, villain or good guy? A brief review
by: Andressa Pereira Cabral, et al.
Published: (2025-01-01)

Proximal bronchiolar adenoma with malignant transformation to invasive mucinous adenocarcinoma with 4 years follow-up: a case report and literature review
by: Yuan-Hui Yang, et al.
Published: (2025-01-01)

Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer
by: Joshua Mangerel, MD, et al.
Published: (2025-03-01)

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
by: Roberto Buonaiuto, et al.
Published: (2025-02-01)

Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus
by: Maofei Zhu, et al.
Published: (2025-01-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)

Clinical Gynecologic Endocrinology and Infertility /
by: Fritz, Marc A.
Published: (2011)

Individual management and prognostic assessment for long-term outcomes using a novel classification system of craniopharyngiomas: a retrospective study of single institution
by: Sen Zhang, et al.
Published: (2025-01-01)

ENDOCRINE DISORDERS IN DOGS: EPIDEMIOLOGY, CLINICAL PRESENTATION, AND DIAGNOSTIC METHODS
by: Daniela Neagu, et al.
Published: (2024-08-01)

Thematic Review of Endocrine Disruptors and Their Role in Shaping Pubertal Timing
by: And Demir, et al.
Published: (2025-01-01)

Modeling the endocrine control of vitellogenin production in female rainbow trout
by: Kaitlin Sundling, et al.
Published: (2013-12-01)